Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.

Share:
More In Business
Turning Unused PTO Into Cold, Hard Cash
Veetahl Eilat-Raichel, Founder and CEO of Sorbet, shares how employees can harness the value of their time off – and how companies can use PTO to employees’ benefit.
Load More